Does Tofacitinib improve disease signs and symptoms and maintain safety in Canadian patients with Rheumatoid Arthritis?
Tofacitinib demonstrated sustained effectiveness and a consistent safety profile over 36 months in Canadian patients with rheumatoid arthritis.
Tofacitinib provided early and sustained improvement of disease signs and symptoms in patients with RA in Canada. Safety was consistent with the RA clinical program and the established tofacitinib clinical profile. Results were consistent with the interim analysis.
Haraoui et al. (Mon,) studied this question.